Sareum

Sareum is a drug discovery and development company, headquartered in Cambridge UK, that produces targeted small molecule therapeutics, focusing on cancer and autoimmune disease. Sareum aims to successfully deliver drug candidates for licensing to pharmaceutical and biotechnology companies at the pre-clinical or early clinical trials stage.

Sareum operates an outsourced research model, working with collaborators (SRI International, the CRT Pioneer Fund and Hebei Medical University Biomedical Engineering Center) and a world-wide network of research providers. Its research pipeline includes two programmes undergoing pre-clinical IND-enabling studies.

Selcia Ltd

Contract Research Services in Integrated Drug Discovery and Custom Radiolabelling. A leading worldwide provider of integrated drug discovery, medicinal chemistry and GMP certified 14C custom radiolabelling services, Selcia is a self-funded, profitable, private company with around 80 employees operating from state-of-the-art laboratories. SELCIA DISCOVERY offers integrated drug discovery services including screening biology, medicinal chemistry, ADME/PK and in vivo PK work.
Company Type
Company Sub-Type
Keywords
Twitter Account
@SelciaLtd

Sphere Fluidics

Encapsulating Biology, Transforming Discovery. #SphereFluidics is developing picodroplets and single cell analysis systems and services for therapeutic discovery.

Specialties:
biopharmaceutical, lab-on-a-chip, cells, antibodies, microfluidics, enzymes, cancer, biologics, biotechnology, pharmaceutical, life sciences, immunology, oncology, cell therapies, and stem cells

Company Type
Company Sub-Type
Twitter Account
@SphereFluidics

Sygnature Discovery Ltd

Sygnature Discovery is the UK’s largest independent provider of integrated drug discovery resource and expertise.  Founded in 2004, Sygnature undertakes complete drug discovery programmes and target validation, hit identification, hit-to-lead and lead optimisation projects for pharmaceutical and biotech companies.  Core capabilities include medicinal and synthetic chemistry, in vitro biology/screening, computational chemistry, DMPK and protein crystallography.  Sygnature has an enviable track record of success in delivering multiple clinical candidates.

Company Type
Company Sub-Type
Twitter Account
@SygnatureDiscov

Syne qua non Ltd

Syne qua non, established in 1996, is one of the largest functional biometrics suppliers in Europe providing global pharma, biotech, medical device and animal health partners with innovative, cost effective development services specializing in: • clinical data management through optimal process design with paper or EDC data capture solutions • statistical expertise through consultative study design to reporting • effective project management • quality management and consultancy Built on a foundation of CDISC standardization, our flexible and site-friendly EDC tool can be rapidly developed, validated and deployed – built to meet the unique requirements of the study and, coupled with our approach to standardization across all services, will deliver high quality data and in-stream reporting within a competitive pricing model.
Company Type
Company Sub-Type
Twitter Account
@Synequanon

Synpromics Ltd

Synpromics is a life science company focused on the field of synthetic biology. The Company's proprietary technology enables the design of optimized synthetic promoters that provide more effective and efficient gene regulation.
Company Type
Company Sub-Type
Twitter Account
@synpromics

SYNthesis Med Chem

SYNthesis med chem, founded in 2007, is a relatively new player in the chemistry CRO market. We are Australian owned with laboratory facilities in Shanghai China and offices in Australia, the US and the UK. The management team at SYNthesis are experienced drug discovery professionals with expertise across a range of targets (particularly Kinases, GPCRs and epigenetic targets).

Our clients are drawn from biotech, big pharma and academia, we have an outstanding client return rate with several clients working with us across two or more target classes.